Docaravimab, Miromavimab

Docaravimab and Miromavimab are two monoclonal antibodies used in the treatment of various medical conditions. They belong to a class of drugs known as immunoglobulin G (IgG) antibodies, which are designed to target specific proteins or cells in the body.
Docaravimab specifically targets a protein called vascular endothelial growth factor (VEGF), which plays a key role in angiogenesis – the formation of new blood vessels. By binding to VEGF, Docaravimab inhibits the growth of new blood vessels, making it an effective treatment for conditions such as wet age-related macular degeneration and diabetic macular edema, both of which involve abnormal blood vessel growth in the retina.
Miromavimab, on the other hand, is an antibody that targets the human immunodeficiency virus (HIV). By binding to a specific protein on the surface of HIV cells, Miromavimab prevents the virus from infecting healthy cells and helps to reduce the viral load in the body. This makes it an important component in the management of HIV infection and AIDS, when used in combination with other antiretroviral therapies.